Abstract
BackgroundImmune checkpoint inhibitors (ICIs) particularly those targeting the PD-1/PD-L1 axis have markedly impacted cancer immunotherapy resulting in significant therapeutic responses across an increasingly wide variety of cancers. While obesity is...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have